# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Robert Burns reiterates Kronos Bio (NASDAQ:KRON) with a Buy and maintains $2.25 price target.
Kronos Bio (NASDAQ:KRON) reported quarterly losses of $(0.27) per share. The company reported quarterly sales of $2.69 million ...
HC Wainwright & Co. analyst Robert Burns reiterates Kronos Bio (NASDAQ:KRON) with a Buy and maintains $2.25 price target.
— KB-0742 cleared 80mg four-days-on, three-days-off dosing schedule in dose escalation — — Company expects to provide an effica...